Oncolytics Biotech’s (ONCY) Buy Rating Reiterated at HC Wainwright

Oncolytics Biotech (NASDAQ:ONCY)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $5.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the company. Leede Financial downgraded Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Royal Bank of Canada cut their price target on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

Shares of NASDAQ:ONCY traded down $0.03 during trading on Monday, reaching $0.66. The stock had a trading volume of 159,260 shares, compared to its average volume of 1,374,521. Oncolytics Biotech has a 52 week low of $0.60 and a 52 week high of $1.53. The firm’s fifty day moving average is $0.78 and its 200 day moving average is $0.93. The stock has a market cap of $56.26 million, a price-to-earnings ratio of -2.44 and a beta of 1.18.

Hedge Funds Weigh In On Oncolytics Biotech

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in shares of Oncolytics Biotech by 59.6% in the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after purchasing an additional 24,997 shares during the last quarter. International Assets Investment Management LLC grew its position in Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after purchasing an additional 26,069 shares in the last quarter. Vantage Point Financial LLC purchased a new stake in Oncolytics Biotech in the 4th quarter valued at about $27,000. National Bank of Canada FI lifted its position in shares of Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after buying an additional 42,955 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech in the 4th quarter worth approximately $90,000. 6.82% of the stock is currently owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.